Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK8 | P45983 | 1/20 | 0.36 |
| ▸ | WHR1 | P49842 | 2/20 | 0.35 |
| ▸ | JAK3 | P52333 | 1/20 | 0.33 |
| ▸ | IDH1 | O75874 | 3/20 | 0.32 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.32 |
| ▸ | CFD | P00746 | 1/20 | 0.31 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.31 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.31 |
| ▸ | KDM1A | O60341 | 1/20 | 0.31 |
| ▸ | IDH2 | P48735 | 1/20 | 0.31 |
| ▸ | CETP | P11597 | 1/20 | 0.31 |
| ▸ | CNR1 | P21554 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.31 |
| ▸ | CNR2 | P34972 | 1/20 | 0.30 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.30 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24810582 | 0.88 | CNR1 (0.39) | WHR1IDH1LRRK2ABCB1KDM1A | |
| SCHEMBL24811091 | 0.86 | MAPK8 (0.38) | MAPK8WHR1JAK3CFDHCRTR2 | |
| SCHEMBL24810574 | 0.84 | ALDH1A1 (0.41) | CNR1ALDH1A1CNR2MAPT | |
| SCHEMBL24810656 | 0.83 | HPGDS (0.36) | ALDH1A1MAPT | |
| SCHEMBL24809752 | 0.81 | HCRTR2 (0.37) | MAPK8HCRTR2CETPALDH1A1MAPT | |
| SCHEMBL24809418 | 0.78 | CNR2 (0.41) | KDM1ACNR2 | |
| SCHEMBL24810591 | 0.73 | EPHX2 (0.39) | IDH1LRRK2ABCB1KDM1ACNR1 | |
| SCHEMBL24810575 | 0.70 | — | — | |
| SCHEMBL24809346 | 0.68 | ASAH1 (0.38) | ALDH1A1MAPT | |
| SCHEMBL24809411 | 0.67 | CHRM4 (0.40) | CNR1ALDH1A1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220411388-A1 | SUBSTITUTED IMIDAZOLE CARBOXAMIDES AND THEIR USE IN THE TREATMENT OF MEDICAL DISORDERS | BIAL R&D INVEST S A (PT) | 2022-12-29 | — | — | US | disclosed |
| EP-4031531-A1 | SUBSTITUTED IMIDAZOLE CARBOXAMIDES AND THEIR USE IN THE TREATMENT OF MEDICAL DISORDERS | Bial-R&D Investments, S.A. (PT) | 2022-07-27 | — | — | EP | disclosed |
| CN-114787135-A | Substituted imidazole carboxamides and their use in the treatment of medical disorders | 比亚尔R&D投资股份公司 | 2022-07-22 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220411388-A1 | SUBSTITUTED IMIDAZOLE CARBOXAMIDES AND THEIR USE IN THE TREATMENT OF MEDICAL DISORDERS | GBA1, GAA, CLN6 | MAPK8 3847/4885WHR1 4586/4885JAK3 1802/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.